The IMGN stock trades on Nasdaq All Markets
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Built with stability and optimizing payload efficacy in mind, our engineered linkers are a hallmark of our ADC designs. Our scientists have created linkers that are stable outside cancer cells but are also able to break—or cleave —once inside cancer cells. The result is a released payload that is also able to enter and kill neighboring cancer cells.
Source: Immunogen, Inc. - 20221121
Non-Small-Cell Lung Cancer
Triple-Negative Breast Cancer
Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm